Initial Public Offering
Baird served as a co- manager on this offering.
AboutNivalis Therapeutics, Inc. (“Nivalis” or the “Company”) (NASDAQ: NVLS) recently completed an initial public offering of 6,325,000 shares of its common stock at a price of $14.00 per share, generating gross proceeds of $88 million. The Company intends to use the net proceeds from the offering for the continued development of the lead product, N91115 and general corporate purposes.
Nivalis is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of small molecule therapeutics for patients with cystic fibrosis. In addition to bringing innovative solutions that extend and improve the lives of people with cystic fibrosis, Nivalis plans to utilize its portfolio of proprietary S-nitrosoglutathione reductase (GSNOR) inhibitors to develop therapeutics portfolio for patients with other diseases. The Company owns exclusive rights to its lead candidate, N91115, in the United States, Europe and all other major markets, including composition of matter patent protection until at least 2031. Nivalis is headquartered in Boulder, Colorado.
For additional information about this transaction, please contact:
- July 2015
- Nivalis Therapeutics, Inc.
- Target Location
- North America